concept

TAUOPATHY

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAUOPATHY: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1553Connections

1Hypotheses

5Analyses

50Outgoing

50Incoming

2Experiments

5Debates

Summary

TAUOPATHY is a concept in neurodegeneration research. Key relationships include: activates, associated with, inhibits. Associated with ALS, Aging, Als. Connected to 436 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	TAUOPATHY
Key Genes/Proteins	ABCA1, ACHE, Actin, ADNP, AGING, AKT
Related Diseases	Aging, Als, ALS, Alzheimer
Related Pathways	Akt, Alpha-Synuclein

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Melatonin for Tauopathy: Comprehensive Evidence Synthesis

therapeutic · 4539 words

→

Pathway Diagram

graph TD
    TAUOPATHY["TAUOPATHY"]
    TAUOPATHY -->|"causes"| lipid_droplets["lipid droplets"]
    TAUOPATHY -->|"activates"| ALS["ALS"]
    TAUOPATHY -->|"activates"| Neurodegeneration["Neurodegeneration"]
    TAUOPATHY -->|"activates"| Alzheimer["Alzheimer"]
    TAUOPATHY -->|"activates"| Tauopathy["Tauopathy"]
    TAUOPATHY -->|"expressed in"| Aging["Aging"]
    TAUOPATHY -->|"expressed in"| Dementia["Dementia"]
    JUN["JUN"] -->|"target for"| TAUOPATHY
    APOE["APOE"] -->|"activates"| TAUOPATHY
    ABCA1["ABCA1"] -->|"target for"| TAUOPATHY
    RAB7A["RAB7A"] -->|"activates"| TAUOPATHY
    CHMP6["CHMP6"] -->|"activates"| TAUOPATHY
    RAB35["RAB35"] -->|"activates"| TAUOPATHY
    BMAL1["BMAL1"] -->|"inhibits"| TAUOPATHY
    BAG3["BAG3"] -->|"activates"| TAUOPATHY
    CLOCK["CLOCK"] -->|"activates"| TAUOPATHY
    TYROBP["TYROBP"] -->|"expressed in"| TAUOPATHY

Outgoing (657)

Target	Relation	Type	Str
Neurodegeneration	associated_with	disease	1.00
Alzheimer	activates	disease	1.00
Neurodegeneration	associated_with	disease	1.00
Alzheimer	associated_with	disease	1.00
Neurodegeneration	activates	disease	1.00
Alzheimer	associated_with	disease	1.00
Alzheimer	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
Tauopathy	activates	disease	1.00
Tauopathy	associated_with	disease	1.00
Autophagy	activates	pathway	1.00
MICROGLIA	activates	gene	1.00
Autophagy	activates	pathway	1.00
Tauopathy	expressed_in	disease	0.95
Als	activates	disease	0.95
Als	associated_with	disease	0.95
Microtubule	causes	protein	0.85
oxidative stress response	involves	pathway	0.85
Inflammation	activates	disease	0.85
Tauopathy	therapeutic_target	disease	0.85
Alzheimer	therapeutic_target	disease	0.85
lipid accumulation	causes	phenotype	0.85
Tauopathy	regulates	disease	0.85
Tauopathy	inhibits	disease	0.85
Senescent Microglia	associated_with	cell_type	0.80
MICROGLIA	regulates	gene	0.80
AUTOPHAGY	activates	gene	0.80
Neurodegeneration	inhibits	disease	0.75
Neurodegeneration	regulates	disease	0.75
Als	causes	disease	0.75
Cancer	activates	disease	0.75
Alzheimer	causes	disease	0.75
Dementia	expressed_in	disease	0.75
Als	activates	disease	0.75
Alzheimer	treats	disease	0.75
Neuroinflammation	treats	disease	0.75
Aging	expressed_in	disease	0.75
Alzheimer	inhibits	disease	0.75
Inflammation	treats	disease	0.75
Alzheimer	expressed_in	disease	0.75
Huntington	activates	disease	0.75
Inflammation	activates	disease	0.75
Neuroinflammation	regulates	disease	0.75
Inflammation	regulates	disease	0.75
Alzheimer	regulates	disease	0.75
Neuroinflammation	activates	disease	0.75
Dementia	associated_with	disease	0.75
unfolded protein response	involves	pathway	0.75
autophagy pathway	involves	pathway	0.75
Tauopathy	interacts_with	disease	0.75

Incoming (896)

Source	Relation	Type	Str
ALZHEIMER'S DISEASE	activates	gene	1.00
TAUOPATHY	associated_with	gene	1.00
TAU	associated_with	gene	1.00
TAU	associated_with	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
AMYLOID	activates	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
NEURODEGENERATIVE DISEASES	activates	gene	1.00
MICROGLIA	activates	gene	1.00
TAUOPATHY	activates	gene	1.00
TAU	activates	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
NEURODEGENERATION	activates	gene	1.00
ALZHEIMER	activates	gene	1.00
ALZHEIMER	activates	gene	1.00
NEURODEGENERATIVE DISEASES	activates	gene	1.00
ALZHEIMER	associated_with	gene	1.00
ALZHEIMER	associated_with	gene	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
TAU	activates	gene	1.00
NEURODEGENERATION	activates	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
AMYLOID	activates	gene	1.00
TAU	biomarker_for	protein	0.95
MAPT	causes	gene	0.95
TAUOPATHY	expressed_in	gene	0.95
AUTOPHAGY	activates	gene	0.95
MAPT	associated_with	gene	0.95
NRF2	therapeutic_target	protein	0.90
TRIAD3A	protects_against	protein	0.90
calcium dysregulation	associated_with	process	0.90
Lipid Droplet Accumulation	associated_with	phenotype	0.90
34326423	is a potential therapeutic strategy for	paper	0.90
41484454	has neuroprotective effects against	paper	0.90
Ps19 Mouse Model	associated_with	disease	0.90
TAU	associated_with	gene	0.90
TFEB	therapeutic_target	gene	0.90
gaps-4r-tauopathy-biomarkers	describes	wiki	0.90
9H6F2 Antibody	biomarker_for	biomarker	0.88
TAU	regulates	gene	0.85
APP E590D	exacerbates	protein	0.85
Neuroinflammation	interacts_with	process	0.85
NEURODEGENERATION	regulates	gene	0.85
TAUOPATHY	inhibits	gene	0.85
TYROBP Deficiency	protects_against	phenotype	0.85
ALZHEIMER'S DISEASE	therapeutic_target	gene	0.85
ALZHEIMER	therapeutic_target	gene	0.85
Als	associated_with	disease	0.85
TAUOPATHY	therapeutic_target	gene	0.85
TAU	therapeutic_target	gene	0.85

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinf	0.628	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro

Mentioning Analyses (5)

Scientific analyses that reference this entity

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Fluid biomarker pT217Tau demonstrates that soluble tau pathology begin	clinical	Alzheimer's disease	0.500	0.00	human	extracted	N/A
Using 11C-PIB PET and 18F-MK6240 PET imaging, asymptomatic ADAD mutati	neuropathology	Alzheimer's disease	0.500	0.00	in_vivo	extracted	N/A

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213]	Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei	Neuron	2026
Role of TREM2 in neuroinflammation. [PMID:41213496]	Abdulkhaliq AA, Alasiri G, Almoghrabi Y,	Exp Neurol	2026
Synergistic potential of TREM2 agonists and exercise training in Alzheimer's dis [PMID:41494649]	Zhang J, St Pierre Schneider B, Muguerza	Am J Physiol Endocrinol Metab	2026
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvir [PMID:41576929]	Mateus-Tique J, Lakshmi A, Singh B, Iyer	Cancer Cell	2026
Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952]	Li X, Tang X, Zeng J, Duan L, Hou Z et a	Cell	2026
TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393]	Feiten AF, Dahm K, Schlepckow K, van Len	Nat Commun	2026
Large-scale single-cell analysis and in silico perturbation reveal dynamic evolu [PMID:41617928]	Xia P, Shuang S, Fu D, Liu L, Yang D et	NPJ Precis Oncol	2026
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant [PMID:41720086]	Zhao Q, Huang R, Wang C, Hu J, Nie R et	Cancer Cell	2026
TREM2 in neurodegeneration and diseases. [PMID:41792456]	["Abdulkhaliq A", "Alasiri G", "Kim B",	Molecular psychiatry	2026
Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721]	Aranda-Abreu GE, Rojas-Durán F, Hernánde	Neurology international	2026
Molecular mechanism of Alzheimer's disease using integrated multi-omics. [PMID:41907842]	Alhusaini M, Mussa BM, Ilce BY, Alhaj H,	Frontiers in aging neuroscienc	2026
Viral and non-viral cellular therapies for neurodegeneration. [PMID:41585268]	["Srivastav Jyotsna", "Sharma Sachin"]	Frontiers in medicine	2025

Debates (5)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning TAUOPATHY in their description or question text

No additional research found

TAUOPATHY

Understanding Entity Pages

Summary

Wiki Pages (1)

Melatonin for Tauopathy: Comprehensive Evidence Synthesis

Pathway Diagram

Outgoing (657)

Incoming (896)

Targeting Hypotheses (1)

Mentioning Analyses (5)

Does tau aggregation specifically cause PS externalization in living cells versu

Do tau-containing vesicles exhibit unique surface glycosylation patterns that di

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

What determines the specificity of DDR protein recruitment to dilncRNA-induced c

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

Experiments (2)

Related Papers (12)

Debates (5)

While DNAJB1 enhancement showed promise, the debate raised concerns about whethe

The debate identified a critical gap in understanding whether PS exposure is tau

While the study shows 53BP1 forms phase-separated foci driven by dilncRNAs, it's

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

Do tau-containing vesicles exhibit unique surface glycosylation patterns that di

Related Research